ResMed has revealed its full year net profit jumped 64%.
The sleep disorder and breathing devices company said it?s expanding its focus to fighting insomnia as it doubles down on digital health investments after another year of huge demand for its products.
?Our global team remains focused on supporting patients, providers and physicians - our top priority is to get products directly into the hands of patients who need therapy most,? said CEO Mick Farrell.
ResMed share price dropped more than 2% following the announcement.